Show simple item record

dc.contributor.authorSzwed, Marzena
dc.contributor.authorKania, Katarzyna D.
dc.contributor.authorJozwiak, Zofia
dc.description.abstractBackground Conjugation of anti-neoplastic agents with human proteins is a strategy to diminish the toxic side effects of anthracycline antibiotics. We have developed a novel doxorubicin-transferrin (DOX-TRF) conjugate aimed to direct anticancer drugs against therapeutic targets that display altered levels of expression in malignant versus normal cells. Our previous work has shown that the cellular bio-distribution of the conjugate is dependent on a dynamic balance between influx and efflux processes. Here, we set out to investigate whether P-glycoprotein (P-gp) expression may affect DOXTRF conjugate-induced cellular drug accumulation and cytotoxicity. Results All experiments were carried out on human erythromyeloblastoid cells exhibiting P-gp over-expression (K562/DOX) and its drug sensitive parental line (K562). MTT cytotoxicity, flow cytometry, fluorescence microscopy and RT-PCR assessments revealed that the investigated conjugate (DOX-TRF) possesses a greater cytotoxic potential than free DOX. Conclusion Our data suggest that the newly developed DOXTRF conjugate is a less P-gp dependent substrate than free DOX and, consequently, may be used in a clinical setting to increase treatment efficacy in resistant human tumors.pl_PL
dc.description.sponsorshipGrant no. 545/ 756 of the University of Lodz, Poland.pl_PL
dc.publisherInternational Society for Cellular Oncology, IOS Presspl_PL
dc.relation.ispartofseriesCell Oncology (Dordrecht);(2014) 37
dc.rightsUznanie autorstwa 3.0 Polska*
dc.subjectDrug carrierspl_PL
dc.subjectMultidrug resistancepl_PL
dc.titleRelationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicinpl_PL
dc.contributor.authorAffiliationSzwed Marzena, University of Lodz, Department of Thermobiology, Faculty of Biology and Environmental Protection,pl_PL
dc.contributor.authorAffiliationKania Katarzyna D., Institute for Medical Biology, Laboratory of Transcriptional Regulation.pl_PL
dc.contributor.authorAffiliationJozwiak Zofia, University of Lodz, Department of Thermobiology, Faculty of Biology and Environmental Protection.pl_PL
dc.referencesB. Ríhová, J. Strohalm, O. Hovorka, V. Subr, T. Etrych, P. Chytil, R. Pola, D. Plocová, J. Boucek, K. Ulbrich, Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences. J. Control. Release 127, 110–120 (2008)pl_PL
dc.referencesM.Mazevet, M.Moulin,A. Llach-Martinez, C. Chargari, E.Deutsch, A.M. Gomez, E. Morel, Complications of chemotherapy, a basic science update. Presse Med. 42, e352–e361 (2013)pl_PL
dc.referencesK.J. Patel, O. Trédan, I.F. Tannock, Distribution of the anticancer drugs doxorubicin,mitoxantrone and topotecan in tumors and normal tissues. Cancer Chemother. Pharmacol. 72, 127–138 (2013)pl_PL
dc.referencesC. Mamot, R. Ritschard, A. Wicki, G. Stehle, T. Dieterle, L. Bubendorf, C. Hilker, S. Deuster, R. Herrmann, C. Rochlitz, Tolerability, safety, pharmacokinetics, and efficacy of doxorubicinloaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 13, 1234–1241 (2012)pl_PL
dc.referencesB. Ky, P. Vejpongsa, E.T. Yeh, T. Force, J.J. Moslehi, Emerging paradigms in cardiomyopathies associated with cancer therapies. Circ. Res. 113, 754–764 (2013)pl_PL
dc.referencesP.S. Guerreiro, A.S. Fernandes, J.G. Costa, M. Castro, J.P. Miranda, N.G. Oliveira, Differential effects of methoxyamine on doxorubicin cytotoxicity and genotoxicity inMDA-MB-231 human breast cancer cells. Mut Res. 757, 140–147 (2013)pl_PL
dc.referencesS. Aroui, S. Brahim, M.D. Waard, A. Kenani, Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: a comparative study. Biochem Biophys Res Comm. 391, 419–425 (2010)pl_PL
dc.referencesC.Y. Quan, C. Chang, H.Wei, C.S. Chen, X.D. Xu, S.X. Cheng, X.Z. Zhang, R.X. Zhuo, Dual targeting of a thermo sensitive nanogel conjugated with transferrin and RGD-containing peptide for effective cell uptake and drug release. Nanotechnology 20, 335101 (2009)pl_PL
dc.referencesF. Kratz, Acid-sensitive prodrugs of doxorubicin. Top. Curr. Chem. 283, 73–97 (2008)pl_PL
dc.referencesL.W. Seymour, Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst. 9, 135–187 (1992)pl_PL
dc.referencesF. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55, 3752–3756 (1995)pl_PL
dc.referencesF. Kratz, U. Beyer, T. Roth, N. Tarasova, P. Collery, F. Lechenault, A. Cazabat, P. Schumacher, C. Unger, U. Falken, Transferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacy. J. Pharm. Sci. 87, 338–346 (1998)pl_PL
dc.referencesH.C. Arora,M.P. Jensen, Y. Yuan, A.Wu, S. Vogt, T. Paunesku, G.E. Woloschak, Nanocarriers enhance doxorubicin uptake in drugresistant ovarian cancer cells. Cancer Res. 72, 769–778 (2012)pl_PL
dc.referencesA. Saneja, V. Khare, N. Alam, R.D. Dubey, P.N. Gupta, Advances in P-glycoprotein-based approaches for delivering anticancer drugs: pharmacokinetic perspective and clinical relevance. Expert Opin Drug Deliv. 11, 121–138 (2014)pl_PL
dc.referencesA.A. Kovalev, D.A. Tsvetaeva, T.V. Grudinskaja, Role of ABCcassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp. Oncol. 35, 287–290 (2013)pl_PL
dc.referencesB. Bauer, A.M. Hartz, G. Fricker, D.S. Miller, Modulation of pglycoprotein transport function at the blood–brain barrier. Exp Biol Med. 230, 118–127 (2005)pl_PL
dc.referencesB. LZ, The drug transporter-metabolism alliance: uncovering and defining the interplay. Mol. Pharm. 6, 1631–1643 (2009)pl_PL
dc.referencesC. Bosquillon, Drug transporters in the lung-implication in the biopharmaceutics of inhaled drugs. J. Pharm. Sci. 99, 2240–2255 (2009)pl_PL
dc.referencesS. Endter, U. Becker, N. Daum, H. Huwer, C.M. Lehr,M. Gumbleton, C. Ehrhardt, P-glycoprotein (MDR1) functional activity in human alveolar epithelial cell monolayers. Cell Tissue Res. 328, 77–84 (2007)pl_PL
dc.referencesF.J. Sharom, Complex Interplay between the P-Glycoprotein Multidrug Efflux Pump and the Membrane: Its Role in Modulating Protein Function. Front Oncol (2014). doi:10.3389/fonc.2014.00041pl_PL
dc.referencesA. Berczi, M. Ruthner, V. Szuts, M. Fritzer, E. Schweizner, H. Goldenberg, Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur J Bioch. 213, 427–436 (1993)pl_PL
dc.referencesM. Szwed, A. Matusiak, A. Laroche-Clary, J. Robert, I. Marszalek, Z. Jozwiak, Transferrin as a drug carrier: cytotoxicity, cellular uptake and transport kinetics of doxorubicin transferrin conjugate in the human leukemia cells. Toxicol In Vitro. 28, 187–197 (2014)pl_PL
dc.referencesT. Ikegawa, F. Ushigome, N. Koyabu, S.Morimoto, Y. Shoyama, M. Naito, T. Tsuruo, H. Ohtani, Y. Sawada, Inhibition of P-glycoprotein by orange juice components, polymethoxy flavones in adriamycinresistant human myelogenous leukemia (K562/ADM) cells. Cancer Lett. 160, 21–28 (2000)pl_PL
dc.referencesY. Zhou, M.M. Gottesman, I. Pastan, The extracellular loop between TM5 and TM6 of P-glycoprotein is required for reactivity with monoclonal antibody UIC2. Arch. Biochem. Biophys. 1, 74–80 (1999)pl_PL
dc.referencesR. Gondko, A. Zgirski, M. Adamska, Biostatistics in tasks, 3rd edn. (University of Lodz, Lodz, 2011), pp. 135–141pl_PL
dc.referencesG. Lehne, D.R. Sørensen, G.E. Tjønnfjord, C. Beiske, T.A. Hagve, H.E. Rugstad, O.P. Clausen, The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice. Leukemia 16, 2388– 2394 (2002)pl_PL
dc.referencesM.R. Grey, R. Burgess, A. Fisher, J.A. Yin, Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in chronic lymphocytic leukaemia. Leuk. Res. 23, 29–35 (1999)pl_PL
dc.referencesS. Lo, B. Tolner, J.W. Taanman, J.M. Cooper, M. Gu, J.A. Hartley, A.H. Schapira, D. Hochhauser, Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents. Int. J. Oncol. 27, 337–344 (2005)pl_PL
dc.referencesP.S. Lai, C.L. Pai, C.L. Peng, M.J. Shieh, K. Berg, P.J. Lou, Enhanced cytotoxicity of saporin by polyamidoamine dendrimer conjugation and photochemical internalization. J Biomed Mater Res. A 87, 147–155 (2008)pl_PL
dc.referencesM.J. Shieh, C.L. Peng, P.J. Lou, C.H. Chiu, T.Y. Tsai, C.Y. Hsu, C.Y. Yeh, P.S. Lai, Nontoxic photo-triggered gene transfection by PAMAM–porphyrin conjugates. J. Drug Target. 15, 279–284 (2007)pl_PL
dc.referencesJ.J. Yu, H.A. Lee, J.H. Kim, W.H. Kong, Y. Kim, Z.Y. Cui, K.G. Park,W.S. Kim, H.G. Lee, S.W. Seo, Bio-distribution and anti-tumor efficacy of PEG/PLA nanoparticles loaded doxorubicin. J. Drug Target. 15, 279–284 (2007)pl_PL
dc.referencesJ.C. Wang, B. Goh, W.L. Lu, Q. Zhang, A. Chang, X.Y. Liu, T.M. Tan, H. Lee, In vitro cytotoxicity of stealth liposomes coencapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28, 822–828 (2005)pl_PL
dc.referencesH.L.Wong, R. Bendayan, A.M. Rauth, X.Y.Wu,Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci. 93, 1993–2008 (2004)pl_PL
dc.referencesJ.Wu, Y. Lu, A. Lee, X. Pan, X. Yang, X. Zhao, R.J. Lee, Reversal of multidrug resistance by transferrin-conjugated liposomes coencapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350–357 (2007)pl_PL
dc.referencesC. Mamot, D.C. Drummond, K. Hong, D.B. Kirpotin, J.W. Park, Liposome-based approaches to overcome anticancer drug resistance. Drug Resis Updates. 6, 271–279 (2003)pl_PL
dc.referencesK. Zhang, W. Chen, T. Bu, H. Qi, R. Sun, X. He, Decreased Pglycoprotein is associated with the inhibitory effects of static magnetic fields and cisplatin on K562 cells. Bioelectromagnetics 35, 437–443 (2014)pl_PL

Files in this item


This item appears in the following Collection(s)

Show simple item record

Uznanie autorstwa 3.0 Polska
Except where otherwise noted, this item's license is described as Uznanie autorstwa 3.0 Polska